Chronic Adaptive versus Conventional Deep Brain Stimulation in Patients with Parkinson's Disease: A Randomized Crossover Trial with Exploratory Analysis of Baseline-Dependent Response Patterns

Jun Tanimura[1,3,✉], Takehiro Yako[2], and Takao Hashimoto[1]

[1]Department of Neurology, Aizawa Hospital, 2-5-1 Honjo, Matsumoto, Nagano 390-0814, Japan
[2]Department of Neurosurgery, Aizawa Hospital, 2-5-1 Honjo, Matsumoto, Nagano 390-0814, Japan
[3]Present address: Emory National Primate Research Center, Emory University, 954 Gatewood Road NE, Atlanta, GA 30329

Background: Adaptive deep brain stimulation (aDBS) modulates stimulation based on real-time biomarkers, potentially offering advantages over conventional DBS (cDBS). Clinical evidence under chronic stimulation remains inconclusive. *Objective*: To compare aDBS versus cDBS efficacy in Parkinson's disease under chronic stimulation and explore baseline-dependent patterns of comparative treatment response across outcomes. *Methods*: This was a double-blind, randomized crossover trial in nine Parkinson's disease patients with bilateral subthalamic nucleus DBS. Patients underwent consecutive one-month periods of cDBS and aDBS after a four-month postoperative interval, administered in randomized order. aDBS was delivered using the dual-threshold algorithm that adjusted amplitude in response to subthalamic beta-band LFP power. Primary outcomes were daily ON/OFF durations and dyskinesia duration under optimized medication. A mixed-effects analysis of covariance estimated treatment effects with false discovery rate adjustments. Exploratory analyses examined treatment-by-baseline interactions to characterize patterns of effect modification across outcomes. *Results*: No statistically significant differences emerged between the aDBS and cDBS results. However, heterogeneous directional effects were observed: ON duration measures favored cDBS (1.91 h/day shorter in aDBS), while duration of troublesome dyskinesias (0.10 h/day shorter in aDBS) and total UPDRS scores (5.93 points lower in aDBS) favored aDBS. There was substantial between-patient heterogeneity. Exploratory analyses suggested an overall pattern that higher baseline disease burden enhanced cDBS advantages for motor fluctuations and aDBS advantages for motor severity, though the direction and magnitude of modification effects varied across outcome–baseline combinations. *Conclusions*: aDBS and cDBS showed no significant differences across clinical outcomes under chronic stimulation with optimized medication. The baseline clinical characteristics of patients may shape the results of aDBS. These findings support comparable efficacy between treatments, warranting larger trials to identify patient subgroups who may benefit from each stimulation approach.

Parkinson's disease | adaptive deep brain stimulation (aDBS) | predictor

Correspondence: *tanimura.jun@gmail.com*

Introduction

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for Parkinson's disease (PD), being particularly beneficial for patients who experience motor fluctuations or medication-induced dyskinesias [1-4]. Conventional DBS (cDBS) provides continuous stimulation at a fixed amplitude, whereas adaptive DBS (aDBS) modulates the stimulation amplitude in real-time, guided by physiological biomarkers such as local field potential (LFP) activity recorded directly from implanted electrodes [5-7]. The aDBS approach, particularly utilizing STN beta-band oscillations (̃13-30 Hz) peak power amplitude as biomarkers, is based on foundational studies demonstrating their relationship with motor symptoms such as bradykinesia and rigidity[8-12]. The rationale for the use of aDBS is to maintain symptom control while reducing unnecessary stimulation, conserving battery life, and potentially minimizing side effects[13].

Despite this promising rationale, clinical evidence supporting the use of aDBS over cDBS remains inconclusive[13]. Pioneering studies with well-controlled exploratory designs consistently demonstrated that aDBS resulted in better motor outcomes[14,15]. However, more real-world-oriented follow-up studies, which carefully eliminated perioperative acute-lesion effects or assessed patients under anti-parkinsonian medication, showed no difference in motor outcomes when aDBS was compared to cDBS[16,17], whereas aDBS was suggested to have advantages in dyskinesia score improvement over cDBS[17]. The issue remains unsettled due to short stimulation periods in previous studies, warranting more comprehensive assessment under real-world practice conditions to clarify the comparative effects of aDBS and cDBS.

Furthermore, optimal patient selection criteria for aDBS have yet to be established[18]. Although a recent Delphi consensus reached agreement that patients with pronounced motor fluctuations and dyskinesias are most likely to benefit from adaptive stimulation[18], clinical evidence from long-term, blinded studies remains limited. Given individual variations in dis-

ease characteristics and outcome priorities, identifying how clinical characteristics at baseline influence the clinical success of aDBS would be important to enable evidence-based treatment selection tailored to predicted individual treatment response patterns.

In this study, we used a clinically available dual-threshold aDBS algorithm that continuously adjusted stimulation amplitude according to beta-band LFP activity power in the STN. We assessed the clinical efficacy of aDBS versus cDBS in patients with PD using a double-blind, randomized, crossover study design. To ensure assessment under stable chronic conditions, evaluations were performed after a postoperative stabilization period of more than four months and after one month of each stimulation method (in random order) under optimized antiparkinsonian medication. Subsequently, we explored predictors of aDBS effectiveness, including demographic characteristics and baseline clinical scores.

Methods

Study Design and Participants

We conducted a two-period, double-blind, crossover randomized controlled trial comparing adaptive DBS (aDBS) with conventional DBS (cDBS) in patients with Parkinson's disease (Figure 1). The trial employed a 1:1 allocation ratio and aimed to assess treatment differences between the two stimulation modes. The primary analysis was designed to test for treatment differences, followed by exploratory analyses examining baseline-dependent effect modification of comparative treatment response across outcomes between aDBS and cDBS.

Eligible participants were patients with a clinical diagnosis of Parkinson's disease, aged under 75 years, with motor complications (motor fluctuations and/or dyskinesia). We excluded patients with cognitive impairment (MMSE < 24), or with significant psychiatric symptoms requiring treatment changes. All participants were recruited from the Movement Disorders Clinic at Aizawa Hospital, Matsumoto, Japan.

Sample Size

Sample size was determined based on effect estimates from previous clinical trials comparing aDBS and cDBS. Because prior studies assessed stimulation over short periods, data on our primary outcomes (ON/OFF time and dyskinesia duration) were not available[14-17]. Instead, we referred to secondary motor outcomes that had been evaluated in prior studies. In particular, differences in UPDRS part III scores between aDBS and cDBS were detected with 8 to 10 study participants[14,15]. Similarly, improvements in dyskinesia scores (Unified Dyskinesia Rating Scale, UDyRS) were detected with approximately 10 participants[17]. Based on these precedents, we aimed to recruit 10-12 participants to evaluate potential treatment differences.

DBS lead implantation surgery

All patients received standard bilateral STN implantation using the Percept PC system (Medtronic, USA), which enables both cDBS and aDBS. Bilateral lead implantation

Fig. 1. Participant flow: randomized two-period crossover. Flow diagram showing numbers screened, randomized, allocated to each first-period sequence, completed, and analyzed, with exclusions and reasons specified at each stage; recruitment and assessment windows are indicated.

was performed in a single operative session. We implanted Medtronic 3387 leads under microelectrode guidance with local anesthesia. Prior to surgery, MRI (including heavy T2-weighted, proton, and gradient echo planar T1 sequences with gadolinium enhancement; MAGNETOM Avanto, Siemens Healthineers, Erlangen, Germany) and non-contrast CT scans were obtained with Leksell G Frame to plan target trajectories using Leksell Surgiplan (Elekta, Stockholm, Sweden). Recording tracks proceeded from anterodorsal to posteroventral at 20-30° from vertical and from lateral to medial at 20° from the sagittal plane. The STN borders were defined physiologically and fitted to atlas maps reconstructed from the Schaltenbrand and Bailey Atlas[19]. Lateral distance to the midline was measured on intraoperative CT scan. We targeted placement of the lowest electrode contact 0-1 mm below the ventral STN border and 10-11 mm lateral to midline, with final electrode locations confirmed by postsurgical MRI. The implantable pulse generator (IPG) was placed subcutaneously in the chest 2–3 days after lead implantation.

Stimulation setting

First, cDBS stimulation settings were made with monopolar stimulation, with the default setting of pulse duration 60 µs and frequency 130 Hz. The stimulation amplitude was initially determined by gradually increasing the amplitude day-by-day and was set just below that producing persistent adverse effects. Patients received cDBS therapy for the first three months after surgery. During the fourth month after surgery, which was one month prior to randomization, we configured the settings for aDBS and tested tolerance for aDBS stimulation over that month.

In this study, we used a clinically available dual-threshold aDBS algorithm that continuously adjusted stimulation amplitude within a programmed range according to beta-band LFP activity power in the STN. We followed the Clinician Programmer Guide[20,21] to set parameters for aDBS. First, we observed LFP with stimulation OFF to define (1) a contact pair to sense the large beta-band peak, which stands out

sharply from the background activity. (2) a stimulating contact for monopolar stimulation, and (3) the range of LFP (Hz) to track (fixed to 5 Hz range). We targeted a peak within 8–30 Hz with a peak amplitude of >1.2 μV[20,21]. We searched for suitable sensing contacts bilaterally and finally chose one ipsilateral contact pair for the bilateral control. Next, LFP threshold values were configured for the Dual Threshold Mode. During the process, the stimulation current was used as an actuator to capture two LFP-power thresholds[20,21]: first, patients received the highest amplitude just below that producing persistent adverse effects (upper therapeutic limit current), and the observed beta power during this stimulation was defined as the lower LFP threshold; subsequently, patients received a lower amplitude (fixed at 20% below the upper therapeutic limit current), and the observed beta power during this stimulation was defined as the upper LFP threshold. (Note that this latter approach for defining the upper LFP threshold deviates from the guidance[20,21]; this fixed 20% reduction—rather than using a level guided by the minimal current needed for symptom improvement—was adopted because, in our experience, it is often difficult to determine the threshold for the initial appearance of parkinsonian symptom improvement reliably.)

Finally, we defined the stimulation setting for aDBS: the higher stimulation current level was set as the upper therapeutic limit used during the LFP-threshold determination process, and the lower stimulation current level was fixed at 20% below the higher level. The ramp time, which is the time of changing between the two stimulation amplitudes, was set to 2.5 min for the upward direction and 5 min for the downward direction. After setting the aDBS program, the setting for cDBS current amplitude was also updated to use the same upper therapeutic limit. The patients entered the randomized crossover periods after confirmation of stable condition for a one-month aDBS period.

Randomization and Integrity of the Blinding

An independent statistician prepared 12 opaque, sealed envelopes containing treatment sequence assignments. Four months after DBS implantation, personnel not involved in patient assessment or data analysis randomly selected and opened one envelope to determine the treatment sequence for each participant. Participants were assigned to receive either cDBS followed by aDBS (Sequence 1) or aDBS followed by cDBS (Sequence 2), with each treatment period lasting one month (Figure 1). Both participants and outcome assessors remained blinded throughout the study. Device programming was performed by independent, unblinded personnel who were not involved in outcome assessments. All analyses were conducted only after completion of all blinded assessments. Participants were not systematically asked which stimulation mode they believed they received.

Outcomes

Clinical outcomes were assessed at the end of each one-month treatment period. Baseline ("preoperative") values for all outcomes were obtained during an inpatient admission within 7 days prior to DBS implantation. Primary outcomes were daily ON time, OFF time, and dyskinesia du-

Variable	Median [IQR] or N (%)
Female, n (%)	4 (44.4%)
Male, n (%)	5 (55.6%)
Age, y	62 (54–65)
Disease duration, y	10 (8–11)
LEDD, mg/day	932 (881–1182)
ADL (Schwab & England), %	90 (90–100)
Hoehn & Yahr, ON	3 (1–3)
Hoehn & Yahr, OFF	4 (4–4)
UPDRS Part I	1 (0–2)
UPDRS Part II, ON	3 (1–7)
UPDRS Part II, OFF	18 (17–27)
UPDRS Part III, ON	15 (3–18)
UPDRS Part III, OFF	37 (30–47)
UPDRS Part IV	8 (7–10)
UPDRS Total, ON	26 (13–34)
UPDRS Total, OFF	69 (56–86)
ON time, h/day	9.7 (8.0–10.1)
OFF time, h/day	8.3 (7.9–10.0)
Dyskinesia time, troublesome h/day	0.3 (0.1–1.7)
Dyskinesia time, non-troublesome h/day	1.8 (1.0–2.4)
MMSE	29 (28–30)
PDQ-39	45 (30–75)

Table 1. Patient Demographics and Clinical Characteristics. Baseline demographic and clinical characteristics of the study participants at the preoperative assessment [n=9]. UPDRS: Unified Parkinson's Disease Rating Scale; H&Y: Hoehn & Yahr stage; IQR: Interquartile range; MMSE: Mini-Mental State Examination; PDQ-39: Parkinson's Disease Questionnaire; LEDD: Levodopa-equivalent daily dose.

ration (troublesome and non-troublesome), based on diary records averaged over the 7-day diary period. Secondary outcomes included total UPDRS score, individual UPDRS subscales (Parts I, II, III, IV), Mini-Mental State Examination (MMSE), Parkinson's Disease Questionnaire-39 (PDQ-39), and Schwab and England Activities of Daily Living (ADL) Scale. All motor assessments during crossover phases were performed in the medication-ON state with optimized medication.

Statistical Analysis

Primary Analysis

We compared the efficacy of aDBS with that of cDBS. We used a mixed-effects ANCOVA model with fixed effects for treatment, period, sequence, and standardized baseline values, and subject-specific random intercepts estimated using REML, thereby explicitly modeling and quantifying between-patient variability while adjusting for design-related period and sequence effects, as well as baseline differences in the outcome measure assessed prior to surgery[22-24].

Treatment differences (aDBS minus cDBS) were estimated in original units as adjusted mean differences with 95% confidence intervals (CIs), accompanied by standardized effect sizes (Cohen's d). Cohen's d was calculated as the treatment estimate divided by the model residual standard deviation, which represents within-patient variability estimated for each outcome from the crossover design, enabling interpretation of effect size as the magnitude of treatment difference relative to natural within-patient variation. All tests

were two-sided with p-values adjusted for multiple comparisons using the Benjamini-Hochberg method. Time-based outcomes were analyzed on the log(1+x) scale to stabilize variance and handle zero values, with back-transformation of marginal estimates for interpretation on the original scale. For non–time-based outcomes, 95% CIs were obtained using the Wald method, whereas for back-transformed measures, CIs were obtained by the delta method. We tested for differential carryover effects by comparing mixed models with and without a treatment-by-period interaction using likelihood-ratio tests (LRTs)[22,25,26]. Missing data were handled through available case analysis without imputation.

Exploratory Analyses

Exploratory analyses aimed to examine how the patient-specific baseline modifies the relative treatment advantages between aDBS and cDBS. Given the potential for heterogeneous treatment responses, we first quantified between-patient heterogeneity using the intraclass correlation coefficient (ICC)[27], equivalent to the intra-subject correlation coefficient[22], derived from the random intercept variance component of the mixed-effects ANCOVA model in the primary analysis. The ICC was calculated as ICC = $\sigma_b^2/(\sigma_b^2 + \sigma^2)$, where σ_b^2 represents the between-patient variance and σ^2 the residual variance. Values were interpreted according to conventional thresholds[27], where ICC <0.50, 0.50–0.75, 0.75–0.90, and >0.90 indicate poor, moderate, good, and excellent reliability, respectively. In the present context, these categories describe the magnitude of between-patient heterogeneity, with higher ICC values indicating larger heterogeneity.

We then examined patterns of effect modification across outcomes based on baseline characteristics by fitting mixed-effects ANCOVA models including Treatment-by-Baseline interactions[28], with Period, Sequence, and z-scored baseline outcome values as covariates, and patient random intercepts. All baseline modifiers were z-scored and sign-aligned such that higher values indicated higher disease burden. Interaction effects were quantified using model-based correlation coefficients (r) derived from t-statistics via the transformation r = t/(t² + df), with positive values indicating that higher baseline disease burden was associated with greater aDBS benefit relative to cDBS. Correlation coefficients were interpreted using reference thresholds: |r| >= 0.5 indicating moderate-to-strong associations and |r| >= 0.8 indicating strong associations. These analyses were explicitly exploratory and hypothesis-generating; thus no formal hypothesis tests were performed and no multiplicity adjustment was applied.

Analyses were performed using R version 4.3.1 with relevant packages including lme4, lmerTest, and emmeans.

Study Registration and Ethics

The study was approved by the Ethics Committee of Aizawa Hospital (2020-064: R2-37), registered with the UMIN Clinical Trials Registry (UMIN000058937), and conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent.

Fig. 2. Distribution of clinical outcomes across study conditions. For each outcome, distributions at Preoperative, cDBS, and aDBS are shown (violin plots). Data from both randomization groups (1: cDBS→aDBS; 2: aDBS→cDBS) are pooled. Individual points are overlaid (jittered), and black diamonds indicate the median. H&Y: Hoehn & Yahr stage, UPDRS: Unified Parkinson's Disease Rating Scale, MMSE: Mini-Mental State Examination, PDQ-39: Parkinson's Disease Questionnaire, LEDD: Levodopa-equivalent daily dose.

Results

Participants and Baseline Characteristics

Of 10 patients initially enrolled between January 2022 and January 2025, one withdrew due to psychological burden related to participation, leaving 9 patients who completed both randomized periods and were included in the final analysis (Figure 1). Participants were randomized to two sequences: Group 1 (n=5) received cDBS in Phase 1 followed by aDBS in Phase 2, while Group 2 (n=4) received aDBS in Phase 1 followed by cDBS in Phase 2. For each outcome, we analyzed all available observations (18 per measure, except MMSE with 15 observations).

Baseline characteristics are summarized in Table 1. The median age was 62 years (IQR 54–65) with a median disease duration of 10 years (IQR 8–11). Four participants (44.4%) were female. The median LEDD was 932 mg/day (IQR

Fig. 3. Primary crossover ANCOVA: standardized treatment effects (aDBS–cDBS). Standardized effect sizes (Cohen's d; red = positive favors aDBS) from the two-period crossover ANCOVA are shown as lollipop plots by outcome. Gray dashed lines indicate conventional effect size references (0.2 = small, 0.5 = medium, 0.8 = large). The combined table reports absolute aDBS–cDBS differences with 95% confidence intervals (CIs), together with p values and FDR-adjusted q values across outcomes (significance set at q<0.05). The model included Treatment, Period, Sequence, and the z-scored preoperative value of the same outcome as fixed effects, with a patient-level random intercept. H&Y, UPDRS, MMSE, PDQ-39, LEDD.

881–1182), and the Hoehn & Yahr stage was 3 in the ON state (IQR 1–3) and 4 in the OFF state (IQR 4–4). Patients showed moderate to severe motor impairments, with median UPDRS part III scores of 37 in the OFF state and 15 in the ON state. Motor complications were present in all participants (UPDRS part IV median 8). Baseline time outcomes showed median daily ON time of 9.7 hours (IQR 8.0–10.1), OFF time of 8.3 hours (IQR 7.9–10.0), troublesome dyskinesia time of 0.3 hours (IQR 0.1–1.7), and non-troublesome dyskinesia time of 1.8 hours (IQR 1.0–2.4).

Comparison of aDBS with cDBS

Figure 2 shows the distribution of clinical outcomes across preoperative, cDBS, and aDBS conditions. No differential carryover was detected for any outcome using likelihood-ratio tests (all p 0.105, Supplementary Table 1).

The comparison of aDBS versus cDBS revealed heterogeneous treatment effect directions across clinical domains, with no statistically significant differences after adjusting for multiple comparisons (Figure 3). The ON time prolongation achieved with cDBS exceeded that achieved by aDBS by 1.91 hours/day (d = -0.94; q = 0.33). Likewise, the OFF-time reduction achieved with cDBS reduced exceeded that achieved by aDBS by 0.73 hours/day (d = -0.74; q = 0.33). The duration of troublesome dyskinesias showed a minimal change favoring aDBS (-0.10 hours per day; d = 0.35; q = 0.69). Both cDBS and aDBS reduced the total UPDRS score, with the reduction by aDBS exceeding that of cDBS by 5.93 points (95% CI -11.45 to -0.40, d = 1.20; p = 0.04). However, this difference was not significant after adjustments for false discovery (q = 0.33), nor did it reach the 8-point minimal clinically important difference[29]. The reduction in UPDRS Part III scores also showed a larger reduction in the aDBS stimulation periods compared to the cDBS stimulation periods (d = 0.87; q = 0.33), with the estimated difference of -2.68 (95% CI -6.12 to 0.77). However, this difference did not reach the minimal clinically meaningful difference of 5 points[29,30]. Other outcomes showed smaller or mixed effects as detailed in Figure 3.

Exploratory Analyses: Predictors of aDBS Benefit

Between-Patient Heterogeneity

We first evaluated the between-patient variability using the mixed-effects ANCOVA model (see Method). The median The intraclass correlation coefficient (ICC) was 0.67 (IQR 0.50–0.86), indicating moderate-to-substantial between-patient heterogeneity: after adjusting for baseline of the same outcome, sequence, and period, approximately 67% of the remaining modeled variance is attributable to differences between patients rather than within-patient variation (Supplementary Table 2)[27]. This supports the use of the mixed-effects framework and suggests that baseline clinical characteristics may shape treatment response.

Effect Modification Analysis

We examined Treatment-by-Baseline interactions to explore baseline-dependent patterns in the comparative effects of aDBS and cDBS across outcomes (Figure 4). Interactions were quantified using model-based correlation coefficients (r). Across 192 outcome–baseline combinations, 38 interactions (19.8%) showed moderate to strong correlation strength (|r| >= 0.5), with 4 combinations (2.1%) showing strong associations (|r| >= 0.8). The four strongest associations (|r| >= 0.8) all showed that higher disease burden was associated with better outcomes with cDBS over aDBS. These were observed for ON-time outcome with baseline PDQ-39 (r = -0.88) and LEDD (r = -0.83), OFF-time outcome with baseline UPDRS Part IV (r = -0.81), and MMSE outcome with baseline PDQ-39 (r = -0.83). Among all moderate-to-strong associations, 22 (57.9%) showed that higher disease burden was associated with better outcomes with cDBS over aDBS. For example, higher LEDD, higher Hoehn & Yahr stage, higher baseline UPDRS Part IV severity, and worse baseline quality of life score (PDQ-39) were associated with cDBS advantages across multiple outcomes, including ON time elongation, OFF time reduction, and better MMSE scores. These associations were outcome-specific, with particular baseline characteristics linked to distinct domains of cDBS benefit. The remaining 16 associations (42.1%) showed the reverse pattern, whereby higher disease burden was associated with better outcomes with aDBS over cDBS. Specif-

Fig. 4. Exploratory effect-modifier analysis: heatmap of model-based correlation coefficients. Interaction effects between baseline predictors and Treatment (aDBS vs cDBS) are displayed as a heatmap across outcomes. Colors encode the model-based correlation coefficient (r) derived from interaction t-statistics: red indicates "worse baseline → greater aDBS benefit," blue indicates "milder baseline → greater aDBS benefit." Asterisks mark associations with moderate-to-strong correlation strength (* |r| >= 0.5, ** |r| >= 0.8). No multiplicity adjustment was applied; results are hypothesis-generating. H&Y, UPDRS, MMSE, PDQ-39, LEDD.

ically, longer disease duration and higher baseline UPDRS Part I and IV severity were associated with aDBS advantages for UPDRS Part III outcomes, while longer disease duration and higher LEDD were associated with aDBS advantages for non-troublesome dyskinesia time reduction. Full numerical results with 95%CI of r for all outcome–baseline combinations are provided in Supplementary Table S3.

Adverse Events

During the assessment after each one-month treatment period, none of the patients reported adverse events (such as paresthesia, dysarthria, dysphagia etc.). Furthermore, no signs of device-related infections, cerebral hemorrhage, or seizures were observed or reported.

Discussion

Key findings

In this two-period, double-blind crossover trial, we observed no statistically significant differences between aDBS and cDBS. However, ON times tended to be longer and OFF times shorter with cDBS, while aDBS seemed to have more beneficial effects on troublesome dyskinesias and UPDRS scores. Exploratory analyses revealed substantial between-patient heterogeneity and suggested that higher baseline disease burden predicted cDBS advantages for motor fluctuations and aDBS advantages for motor severity outcomes.

Comparison with prior work

Compared to the existing literature, the current study better reflects real-world medical practice, with a substantial post-operative interval before randomization (at least 4 months), chronic stimulation (1 month per mode), and clinical assessment under optimized antiparkinsonian medication. Previous clinical trials of aDBS, combining acute or short-term

stimulation without medication and recent more real-world replicating studies, found mixed results[14-17], and it would be fair to conclude that aDBS would not be superior to cDBS[13]. Our results are consistent with this general view, with no significant differences between the two DBS systems, although minor differences were identified as mentioned above. The magnitude of relative improvement in UPDRS Part III (aDBS–cDBS estimate: -2.68 points; 95% CI -6.12 to 0.77) was smaller than earlier studies (e.g., -11.9 points in Little et al., 2016[15]), potentially due to optimized antiparkinsonian medication in our design and the ANCOVA-based effect size estimation corrected for crossover sequence, period, baseline differences, and between-patient variability. This interpretation is consistent with Rosa et al., 2017[17], who similarly found no significant difference in UPDRS Part III when assessed in the medication-on state. The directional benefit of aDBS for troublesome dyskinesia partially aligns with Rosa 2021[17], who reported improvements in the Unified Dyskinesia Rating Scale, though our study did not show significant difference. The difference may be due to the different outcome measures (time scale measures versus clinical rating scales), ANCOVA-based correction, and our long-term design and its chronic effects of aDBS. Our chronic stimulation design enabled assessment of ON/OFF/dyskinesia time measures as outcomes, where no differences were observed between the two DBS systems, further supporting their clinical relevance. The direction of effect sizes across outcomes was heterogeneous, highlighting the potential importance of individualized goal setting when considering indications for aDBS treatment with current biomarkers[31].

Interpretation and implications

The moderate to high between-participant heterogeneity in our primary analysis suggests that baseline clinical sever-

ity may affect the relative benefit between aDBS and cDBS, which justifies our exploratory effect-modification analyses. The analyses suggested that for UPDRS Part III outcome (ON state), the relative advantages of aDBS — shown in primary analysis — would be further enhanced among patients with longer disease duration and higher baseline burden, particularly in UPDRS Parts I and IV (ON state). These findings align with the expert consensus that patients with fluctuating symptoms may benefit more from aDBS[18]. Similarly, the relative disadvantages of aDBS in non-troublesome dyskinesia reduction would be mitigated among patients with longer disease duration and higher LEDD before surgery. On the other hand, higher disease burdens would also further enhance the relative advantages of cDBS, especially in ON/OFF time outcomes. The observed heterogeneity in directional effects across baseline characteristics suggests outcome-specific preferences of the current aDBS approach with LFP beta-band peak thresholding. Recently highlighted physiological biomarkers such as beta bursts and gamma peaks[32-34] potentially offer advantages for alternative adaptive stimulation approaches through their specific associations with distinct outcomes, enabling more individualized treatment selection based on patient-specific treatment goals.

Limitations and generalizability

The lack of formal sample size estimation in primary outcome potentially limits the statistical power of our study, although it is comparable to previous aDBS clinical trials for our secondary outcome (UPDRS part III)[14-17]. Each stimulation mode was evaluated over a one-month period; although this duration exceeds that of other studies, it still limits its inferences regarding further long-term efficacy or durability of treatment effects over months to years. The beta-band/clinical-symptom correspondence was not confirmed during the study, which may limit our interpretation in terms of the biomarker stability over our extended study period. The exploratory effect-modifier analyses involved multiple unadjusted comparisons with inferences based mainly on correlation coefficient effect sizes; thus, findings from this part of the study need to be replicated. Our study used specific hardware (Percept PC) and LFP-based sensing with beta-band amplitude thresholding; thus, findings should be extrapolated cautiously to other biomarkers, algorithms, or devices. Device-level metrics (time at the higher stimulation amplitude, total energy delivered, battery consumption) were not prospectively collected; future trials should include these endpoints to quantify any energy benefit of aDBS. Being a single-center study in Japan, external validity may be limited for settings with different healthcare systems or patient populations; thus, results should be interpreted cautiously with reference to the baseline characteristics of patients.

Conclusions

In this randomized crossover trial, aDBS and cDBS showed no statistically significant differences across clinical outcomes, whereas directional effects varied by outcome domain. Baseline clinical characteristics may enhance or mitigate the comparative advantages of each treatment approach, suggesting the need for individualized goal prioritization. These findings support the view that aDBS and cDBS have comparable efficacy under chronic stimulation with optimized medication, and warrant confirmation in larger, multicenter trials designed to identify specific patient subgroups who may benefit from the current form of adaptive stimulation.

ACKNOWLEDGEMENTS
The authors thank Dr. Shoji Yomo for his contributions to surgical planning using the SurgePlan system, Dr. Thomas Wichmann for his critical and constructive comments on the manuscript.

FUNDINGS
This research received no external funding. All clinical procedures and routine follow-up were conducted as part of standard care at Aizawa Hospital and supported by institutional resources; no company provided financial or in-kind support.

COMPETING INTERESTS
Jun Tanimura has received honoraria from Eisai and FP Corporation outside of this work. Takehiro Yako and Takao Hashimoto declare no competing interests.

DATA AND CODE AVAILABILITY
All data and code produced in the present study are available upon reasonable request to the authors.

GENERATIVE AI USAGE
The Authors used ChatGPT (OpenAI), Claude (Anthropic), and Gemini (Google) to improve readability, grammar, word choice, and flow. After using these tools, the authors carefully reviewed and edited the content as needed and take full responsibility for the content of the published article.

AUTHOR CONTRIBUTIONS
Jun Tanimura: Conceptualization, Methodology, Formal analysis, Investigation, Data curation, Visualization, Writing – Original draft, Writing – Review & Editing, Project administration
Takehiro Yako: Methodology, Investigation, Resources, Writing – Review & Editing
Takao Hashimoto: Conceptualization, , Methodology, Formal analysisSupervision, Writing – Review & Editing

REFERENCES

1. Follett, K.A., Weaver, F.M., Stern, M., Hur, K., Harris, C.L., Luo, P., Marks, W.J., Jr., Rothlind, J., Sagher, O., Moy, C., et al. (2010). Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med *362*, 2077-2091. 10.1056/NEJMoa0907083.

2. Okun, M.S., Gallo, B.V., Mandybur, G., Jagid, J., Foote, K.D., Revilla, F.J., Alterman, R., Jankovic, J., Simpson, R., Junn, F., et al. (2012). Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol *11*, 140-149. 10.1016/S1474-4422(11)70308-8.

3. Perestelo-Perez, L., Rivero-Santana, A., Perez-Ramos, J., Serrano-Perez, P., Panetta, J., and Hilarion, P. (2014). Deep brain stimulation in Parkinson's disease: meta-analysis of randomized controlled trials. J Neurol *261*, 2051-2060. 10.1007/s00415-014-7254-6.

4. Schuepbach, W.M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Halbig, T.D., Hesekamp, H., Navarro, S.M., Meier, N., et al. (2013). Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med *368*, 610-622. 10.1056/NEJMoa1205158.

5. Beudel, M., and Brown, P. (2016). Adaptive deep brain stimulation in Parkinson's disease. Parkinsonism Relat Disord *22 Suppl 1*, S123-126. 10.1016/j.parkreldis.2015.09.028.

6. Habets, J.G.V., Heijmans, M., Kuijf, M.L., Janssen, M.L.F., Temel, Y., and Kubben, P.L. (2018). An update on adaptive deep brain stimulation in Parkinson's disease. Mov Disord *33*, 1834-1843. 10.1002/mds.115.

7. Stanslaski, S., Summers, R.L.S., Tonder, L., Tan, Y., Case, M., Raike, R.S., Morelli, N., Herrington, T.M., Beudel, M., Ostrem, J.L., et al. (2024). Sensing data and methodology from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) clinical trial. NPJ Parkinsons Dis *10*, 174. 10.1038/s41531-024-00772-5.

8. Kuhn, A.A., Kempf, F., Brucke, C., Gaynor Doyle, L., Martinez-Torres, I., Pogosyan, A., Trottenberg, T., Kupsch, A., Schneider, G.H., Hariz, M.I., et al. (2008). High-frequency stimulation of the subthalamic nucleus suppresses oscillatory beta activity in patients with Parkinson's disease in parallel with improvement in motor performance. J Neurosci *28*, 6165-6173. 10.1523/JNEUROSCI.0282-08.2008.

9. Kuhn, A.A., Kupsch, A., Schneider, G.H., and Brown, P. (2006). Reduction in subthalamic 8-35 Hz oscillatory activity correlates with clinical improvement in Parkinson's disease. Eur J Neurosci *23*, 1956-1960. 10.1111/j.1460-9568.2006.04717.x.

10. Ray, N.J., Jenkinson, N., Wang, S., Holland, P., Brittain, J.S., Joint, C., Stein, J.F., and Aziz, T. (2008). Local field potential beta activity in the subthalamic nucleus of patients with Parkinson's disease is associated with improvements in bradykinesia after dopamine and deep brain stimulation. Exp Neurol *213*, 108-113. 10.1016/j.expneurol.2008.05.008.

11. Weinberger, M., Mahant, N., Hutchison, W.D., Lozano, A.M., Moro, E., Hodaie, M., Lang, A.E., and Dostrovsky, J.O. (2006). Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol *96*, 3248-3256. 10.1152/jn.00697.2006.

12. Bergman, H., Wichmann, T., Karmon, B., and DeLong, M.R. (1994). The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol *72*, 507-520. 10.1152/jn.1994.72.2.507.

13. Little, S., and Brown, P. (2020). Debugging Adaptive Deep Brain Stimulation for Parkinson's Disease. Mov Disord *35*, 555-561. 10.1002/mds.27996.

14. Little, S., Pogosyan, A., Neal, S., Zavala, B., Zrinzo, L., Hariz, M., Foltynie, T., Limousin, P., Ashkan, K., FitzGerald, J., et al. (2013). Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol *74*, 449-457. 10.1002/ana.23951.

15. Little, S., Tripoliti, E., Beudel, M., Pogosyan, A., Cagnan, H., Herz, D., Bestmann, S., Aziz, T., Cheeran, B., Zrinzo, L., et al. (2016). Adaptive deep brain stimulation for Parkinson's disease demonstrates reduced speech side effects compared to conventional stimulation in the acute setting. J Neurol Neurosurg Psychiatry *87*, 1388-1389. 10.1136/jnnp-2016-313518.

16. Pina-Fuentes, D., van Dijk, J.M.C., van Zijl, J.C., Moes, H.R., van Laar, T., Oterdoom, D.L.M., Little, S., Brown, P., and Beudel, M. (2020). Acute effects of adaptive Deep Brain Stimulation in Parkinson's disease. Brain Stimul *13*, 1507-1516. 10.1016/j.brs.2020.07.016.

17. Rosa, M., Arlotti, M., Marceglia, S., Cogiamanian, F., Ardolino, G., Fonzo, A.D., Lopiano, L., Scelzo, E., Merola, A., Locatelli, M., et al. (2017). Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients. Mov Disord *32*, 628-629. 10.1002/mds.26953.

18. Guidetti, M., Bocci, T., De Pedro Del Alamo, M., Deuschl, G., Fasano, A., Martinez-Fernandez, R., Gasca-Salas, C., Hamani, C., Krauss, J.K., Kuhn, A.A., et al. (2025). Will adaptive deep brain stimulation for Parkinson's disease become a real option soon? A Delphi consensus study. NPJ Parkinsons Dis *11*, 110. 10.1038/s41531-025-00974-5.

19. Schaltenbrand G, B.P. (1959). Introduction to stereotaxis with an atlas of the human brain. . Stuttgart: Thieme.

20. Jimenez-Shahed, J. (2021). Device profile of the percept PC deep brain stimulation system for the treatment of Parkinson's disease and related disorders. Expert Review of Medical Devices *18*, 319-332. 10.1080/17434440.2021.1909471.

21. Medtronic (2020). Clinician programmer application for deep brain stimulation – clinican programming guide – percept™ pc model b35200 neurostimulator – application version 2.0. Minneapolis, MN: Medtronic, Inc.

22. Li, B., Zhou, Z., Zhang, L., and Yang, Y. (2020). Testing treatment-by-period interaction in four-period crossover trials. Pharm Stat *19*, 145-163. 10.1002/pst.1975.

23. Willan, A.R., and Pater, J.L. (1986). Using baseline measurements in the two-period crossover clinical trial. Control Clin Trials *7*, 282-289. 10.1016/0197-2456(86)90036-x.

24. Byron Jones, M.G.K. (2014). Design and Analysis of Cross-Over Trials, 3rd Edition Edition (Routledge).

25. Dwan, K., Li, T., Altman, D.G., and Elbourne, D. (2019). CONSORT 2010 statement: extension to randomised crossover trials. BMJ *366*, l4378. 10.1136/bmj.l4378.

26. Kenward, M.G., and Jones, B. (1987). The analysis of data from 2 x 2 cross-over trials with baseline measurements. Stat Med *6*, 911-926. 10.1002/sim.4780060806.

27. Koo, T.K., and Li, M.Y. (2016). A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med *15*, 155-163. 10.1016/j.jcm.2016.02.012.

28. Brankovic, M., Kardys, I., Steyerberg, E.W., Lemeshow, S., Markovic, M., Rizopoulos, D., and Boersma, E. (2019). Understanding of interaction (subgroup) analysis in clinical trials. Eur J Clin Invest *49*, e13145. 10.1111/eci.13145.

29. Schrag, A., Sampaio, C., Counsell, N., and Poewe, W. (2006). Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord *21*, 1200-1207. 10.1002/mds.20914.

30. Sanchez-Ferro, A., Matarazzo, M., Martinez-Martin, P., Martinez-Avila, J.C., Gomez de la Camara, A., Giancardo, L., Arroyo Gallego, T., Montero, P., Puertas-Martin, V., Obeso, I., et al. (2018). Minimal Clinically Important Difference for UPDRS-III in Daily Practice. Mov Disord Clin Pract *5*, 448-450. 10.1002/mdc3.12632.

31. Oehrn, C.R., Cernera, S., Hammer, L.H., Shcherbakova, M., Yao, J., Hahn, A., Wang, S., Ostrem, J.L., Little, S., and Starr, P.A. (2024). Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial. Nat Med *30*, 3345-3356. 10.1038/s41591-024-03196-z.

32. Guidetti, M., Marceglia, S., Loh, A., Harmsen, I.E., Meoni, S., Foffani, G., Lozano, A.M., Moro, E., Volkmann, J., and Priori, A. (2021). Clinical perspectives of adaptive deep brain stimulation. Brain Stimul *14*, 1238-1247. 10.1016/j.brs.2021.07.063.

33. Feldmann, L.K., Lofredi, R., Neumann, W.J., Al-Fatly, B., Roediger, J., Bahners, B.H., Nikolov, P., Denison, T., Saryyeva, A., Krauss, J.K., et al. (2022). Toward therapeutic electrophysiology: beta-band suppression as a biomarker in chronic local field potential recordings. NPJ Parkinsons Dis *8*, 44. 10.1038/s41531-022-00301-2.

34. Kehnemouyi, Y.M., Wilkins, K.B., Anidi, C.M., Anderson, R.W., Afzal, M.F., and Bronte-Stewart, H.M. (2021). Modulation of beta bursts in subthalamic sensorimotor circuits predicts improvement in bradykinesia. Brain *144*, 473-486. 10.1093/brain/awaa394.

35. Neumann, W.J., Gilron, R., Little, S., and Tinkhauser, G. (2023). Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation. Mov Disord *38*, 937-948. 10.1002/mds.29415.